Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Eero Kaasinen, Hans Wijkström, Erkki Rintala, Oddvar Mestad, Staffan Jahnson & Per-Uno Malmström. (2016) Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scandinavian Journal of Urology 50:5, pages 360-368.
Read now
Read now
Riikka Järvinen, Eero Kaasinen, Erkki Rintala & The Finnbladder Group. (2012) Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scandinavian Journal of Urology and Nephrology 46:6, pages 411-417.
Read now
Read now
Articles from other publishers (4)
Erin L. J. Alston & Debra L. Zynger. (2019) Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?. Diagnostic Pathology 14:1.
Crossref
Crossref
Abbas Agaimy, Simone Bertz, Arndt Hartmann, Sarah Minner & Guido Sauter. 2016. Pathologie. Pathologie
523
573
.
Eva Compérat, Solene-Florence Jacquet, Justine Varinot, Pierre Conort, Morgan Roupret, Emmanuel Chartier-Kastler, Marc-Olivier Bitker, Johannes Alfred Witjes & Olivier Cussenot. (2013) Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. Virchows Archiv 462:3, pages 343-348.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Urology 22:5, pages 432-443.
Crossref
Crossref